Contribute Try STAT+ Today

Northwest Biotherapeutics has buried data from its completed brain cancer clinical trial for so long and so deeply, I might be one of the few people who remembers that results from the Phase 3 study are still, technically, undisclosed.

“Technically” because biotechs never hide or delay the release of good news. As of Tuesday, the wait for Northwest Bio to disclose study results reached one year. Realistically, the only lingering suspense is how, exactly, management will try to spin the treatment’s failure.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment